HY 014B11
Alternative Names: HY-014B11Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Helperby Therapeutics
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Intra-abdominal infections; Urinary tract infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Intra-abdominal-infections in United Kingdom (PO)
- 28 Nov 2024 No recent reports of development identified for research development in Urinary-tract-infections(Complicated) in United Kingdom (PO)
- 14 Jun 2021 Helperby Therapeutics plans a preclinical trials for Intra-abdominal infections, Urinary tract infections (Complicated) (Helperby Therapeutics pipeline, June 2021)